Showing results (691-700 of 785) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|October 2, 2015
Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort studyLine D Rasmussen, Margaret T May, Gitte Kronborg, et al.
The Lancet. HIV|October 2, 2015
Nurse-led palliative care for HIV-positive patients taking antiretroviral therapy in Kenya: a randomised controlled trialKeira Lowther, Lucy Selman, Victoria Simms, et al.
The Lancet. HIV|October 2, 2015
Associations between HIV and schizophrenia and their effect on HIV treatment outcomes: a nationwide population-based cohort study in DenmarkMarie Helleberg, Marianne G Pedersen, Carsten B Pedersen, et al.
The Lancet. HIV|October 2, 2015
Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort studyMorna Cornell, Leigh F Johnson, Michael Schomaker, et al.
The Lancet. HIV|October 2, 2015
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialNicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
The Lancet. HIV|October 2, 2015
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trialThomas A Rasmussen, Martin Tolstrup, Christel R Brinkmann, et al.
The Lancet. HIV|October 2, 2015
Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysisEdward J Mills, Richard Lester, Kristian Thorlund, et al.
The Lancet. HIV|October 2, 2015
Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort studyNikos Pantazis, Kholoud Porter, Dominique Costagliola, et al.
The Lancet. HIV|October 2, 2015
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b studyJean-Michel Molina, Bonaventura Clotet, Jan van Lunzen, et al.
The Lancet. HIV|July 23, 2017
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP StudyRenee Heffron, R Scott McClelland, Jennifer E Balkus, et al.
Pageof 79